Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

被引：172

作者：

Nagorsen, Dirk ^{[1
,2
]}

Baeuerle, Patrick A. ^{[1
]}

机构：

[1] Micromet Inc, Bethesda, MD 20817 USA

[2] Heidelberg Univ, Univ Med Mannheim, Dept Hematol Oncol, D-6900 Heidelberg, Germany

来源：

EXPERIMENTAL CELL RESEARCH | 2011年 / 317卷 / 09期

关键词：

Bispecific; Antibody; BiTE; TUMOR; REGRESSION;

D O I：

10.1016/j.yexcr.2011.03.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as a new option for the treatment of malignant diseases, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis. Blinatumomab, a bispecific single-chain BiTE antibody construct with dual specificity for CD19 and CD3, is a front runner of this antibody class. We here summarize the current state of development of blinatumomab for the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphocytic leukemia (ALL). High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：1255 / 1260

页数：6

共 22 条

[1] BiTE: a new class of antibodies that recruit T-cells [J].

Baeuerle, P. A. ;

Reinhardt, C. ;

Kufer, P. .

DRUGS OF THE FUTURE, 2008, 33 (02) :137-147

[2] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[3] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J].

Bassan, Renato ;

Spinelli, Orietta ;

Oldani, Elena ;

Intermesoli, Tamara ;

Tosi, Manuela ;

Peruta, Barbara ;

Rossi, Giuseppe ;

Borlenghi, Erika ;

Pogliani, Enrico M. ;

Terruzzi, Elisabetta ;

Fabris, Pietro ;

Cassibba, Vincenzo ;

Lambertenghi-Deliliers, Giorgio ;

Cortelezzi, Agostino ;

Bosi, Alberto ;

Gianfaldoni, Giacomo ;

Ciceri, Fabio ;

Bernardi, Massimo ;

Gallamini, Andrea ;

Mattei, Daniele ;

Di Bona, Eros ;

Romani, Claudio ;

Scattolin, Anna Maria ;

Barbui, Tiziano ;

Rambaldi, Alessandro .

BLOOD, 2009, 113 (18) :4153-4162

[4] Cancer immunotherapy: A treatment for the masses [J].

Blattman, JN ;

Greenberg, PD .

SCIENCE, 2004, 305 (5681) :200-205

[5] Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study [J].

Conter, Valentino ;

Bartram, Claus R. ;

Valsecchi, Maria Grazia ;

Schrauder, Andre ;

Panzer-Gruemayer, Renate ;

Moericke, Anja ;

Arico, Maurizio ;

Zimmermann, Martin ;

Mann, Georg ;

De Rossi, Giulio ;

Stanulla, Martin ;

Locatelli, Franco ;

Basso, Giuseppe ;

Niggli, Felix ;

Barisone, Elena ;

Henze, Guenter ;

Ludwig, Wolf-Dieter ;

Haas, Oskar A. ;

Cazzaniga, Giovanni ;

Koehler, Rolf ;

Silvestri, Daniela ;

Bradtke, Jutta ;

Parasole, Rosanna ;

Beier, Rita ;

van Dongen, Jacques J. M. ;

Biondi, Andrea ;

Schrappe, Martin .

BLOOD, 2010, 115 (16) :3206-3214

[6] Use of tumour-responsive T cells as cancer treatment [J].

Disis, Mary L. ;

Bernhard, Helga ;

Jaffee, Elizabeth M. .

LANCET, 2009, 373 (9664) :673-683

[7] T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct [J].

Dreier, T ;

Baeuerle, PA ;

Fichtner, I ;

Grün, M ;

Schlereth, B ;

Lorenczewski, G ;

Kufer, P ;

Lutterbüse, R ;

Riethmüller, G ;

Gjorstrup, P ;

Bargou, RC .

JOURNAL OF IMMUNOLOGY, 2003, 170 (08) :4397-4402

[8] Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens [J].

Dudley, Mark E. ;

Yang, James C. ;

Sherry, Richard ;

Hughes, Marybeth S. ;

Royal, Richard ;

Kammula, Udai ;

Robbins, Paul F. ;

Huang, JianPing ;

Citrin, Deborah E. ;

Leitman, Susan F. ;

Wunderlich, John ;

Restifo, Nicholas P. ;

Thomasian, Armen ;

Downey, Stephanie G. ;

Smith, Franz O. ;

Klapper, Jacob ;

Morton, Kathleen ;

Laurencot, Carolyn ;

White, Donald E. ;

Rosenberg, Steven A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5233-5239

[9]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[10] Tumor microenvironment and immune escape [J].

Ferrone, Soldano ;

Whiteside, Theresa L. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) :755-+

← 1 2 3 →